Loading clinical trials...
Loading clinical trials...
An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Conditions
Interventions
bevacizumab [Avastin]
interferon alfa-2a
Locations
50
Czechia
Olomouc, Czechia
Prague, Czechia
Tallinn, Estonia
Tallinn, Estonia
Tartu, Estonia
Seinäjoki, Finland
Start Date
December 1, 2008
Primary Completion Date
February 1, 2012
Completion Date
February 1, 2012
Last Updated
May 27, 2015
NCT06391099
NCT06349642
NCT07227415
NCT04473781
NCT07294859
NCT07190638
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions